Openly accessible

Uncommon fatty acids and cardiometabolic health

Li, Kelei, Sinclair, Andrew J., Zhao, Feng and Li, Duo 2018, Uncommon fatty acids and cardiometabolic health, Nutrients, vol. 10, no. 10, pp. 1-14, doi: 10.3390/nu10101559.

Attached Files
Name Description MIMEType Size Downloads
sinclair-uncommonfatty-2018.pdf Published version application/pdf 633.24KB 72

Title Uncommon fatty acids and cardiometabolic health
Author(s) Li, Kelei
Sinclair, Andrew J.
Zhao, Feng
Li, Duo
Journal name Nutrients
Volume number 10
Issue number 10
Article ID 1559
Start page 1
End page 14
Total pages 14
Publisher MDPI
Place of publication Basel, Switzerland
Publication date 2018-10-20
ISSN 2072-6643
Keyword(s) antioxidant
blood lipids
cardiovascular disease
conjugated fatty acids
docosapentaenoic acid
furan fatty acids
metabolic disease
Science & Technology
Life Sciences & Biomedicine
Nutrition & Dietetics
Summary Cardiovascular disease (CVD) is a major cause of mortality. The effects of several unsaturated fatty acids on cardiometabolic health, such as eicosapentaenoic acid (EPA) docosahexaenoic acid (DHA), α linolenic acid (ALA), linoleic acid (LA), and oleic acid (OA) have received much attention in past years. In addition, results from recent studies revealed that several other uncommon fatty acids (fatty acids present at a low content or else not contained in usual foods), such as furan fatty acids, n-3 docosapentaenoic acid (DPA), and conjugated fatty acids, also have favorable effects on cardiometabolic health. In the present report, we searched the literature in PubMed, Embase, and the Cochrane Library to review the research progress on anti-CVD effect of these uncommon fatty acids. DPA has a favorable effect on cardiometabolic health in a different way to other long-chain n-3 polyunsaturated fatty acids (LC n-3 PUFAs), such as EPA and DHA. Furan fatty acids and conjugated linolenic acid (CLNA) may be potential bioactive fatty acids beneficial for cardiometabolic health, but evidence from intervention studies in humans is still limited, and well-designed clinical trials are required. The favorable effects of conjugated linoleic acid (CLA) on cardiometabolic health observed in animal or in vitro cannot be replicated in humans. However, most intervention studies in humans concerning CLA have only evaluated its effect on cardiometabolic risk factors but not its direct effect on risk of CVD, and randomized controlled trials (RCTs) will be required to clarify this point. However, several difficulties and limitations exist for conducting RCTs to evaluate the effect of these fatty acids on cardiometabolic health, especially the high costs for purifying the fatty acids from natural sources. This review provides a basis for better nutritional prevention and therapy of CVD.
Language eng
DOI 10.3390/nu10101559
Indigenous content off
Field of Research 1111 Nutrition And Dietetics
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2018 by the authors
Free to Read? Yes
Use Rights Creative Commons Attribution licence
Persistent URL

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Open Access Collection
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 6 times in TR Web of Science
Scopus Citation Count Cited 8 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 175 Abstract Views, 72 File Downloads  -  Detailed Statistics
Created: Fri, 26 Oct 2018, 14:24:14 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact